MimiVax, Inc. and UI Pharmaceuticals have announced the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP’s recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients.
About SurVaxM
SurVaxM is a groundbreaking immunotherapeutic targeting survivin, a cell-survival protein prevalent in glioblastomas and many other cancers. This innovative immunotherapy is engineered to stimulate a patient’s immune system to recognize survivin-expressing cancer cells as foreign, thereby controlling tumor growth and recurrence.
Currently, SurVaxM is being evaluated in a randomized Phase 2b clinical trial for glioblastoma at 11 leading cancer centers across the United States. Additional clinical trials are exploring its potential in multiple myeloma, neuro-endocrine tumors (NET), and pediatric relapsed high-grade glioma. MimiVax’s Glioblastoma treatment using SurVaxM has also received a fast track drug designation by the US FDA
